55 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28242276	45	Synthesis of dihydroimidazole tethered imidazolinethiones and their activity as novel antagonists of the nuclear retinoic acid receptor-related orphan receptors (RORs).	Torrey Pines Institute For Molecular Studies
27815118	112	Discovery of phenoxyindazoles and phenylthioindazoles as ROR¿ inverse agonists.	Galderma R & D
26990539	79	Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR)ß Agonist.	Vitae Pharmaceuticals
27080181	33	Discovery of biaryls as ROR¿ inverse agonists by using structure-based design.	Biogen
26819660	82	SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.	Central Pharmaceutical Research Institute
26905831	11	Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317.	The University of Tokyo
26321361	56	Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.	Genentech
26048806	80	Discovery of biaryl carboxylamides as potent ROR¿ inverse agonists.	Biogen Idec
26048793	91	Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.	Genentech
26048789	143	Discovery of novel pyrazole-containing benzamides as potent ROR¿ inverse agonists.	Biogen
26014484	12	Design and synthesis of novel ROR inverse agonists with a dibenzosilole scaffold as a hydrophobic core structure.	The University of Tokyo
25017032	62	Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.	Genentech
24502334	123	Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc).	Genentech
25453817	130	A reversed sulfonamide series of selective RORc inverse agonists.	Argenta Discovery
25305688	41	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.	Phenex Pharmaceuticals
24702856	84	Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (ROR¿)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.	The University of Tokyo
24685544	75	Identification of tertiary sulfonamides as RORc inverse agonists.	Genentech
24559867	6	Development of novel silicon-containing inverse agonists of retinoic acid receptor-related orphan receptors.	The University of Tokyo
24239186	84	Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.	Genentech
24900700	21	Identification of New Nonsteroidal ROR? Ligands; Related Structure-Activity Relationships and Docking Studies.	Genfit
32334911	22	Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (ROR?t) agonists.	Bristol Myers Squibb
32551004	32	Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist.	Bristol Myers Squibb
30776227	38	Discovery of Second Generation ROR? Inhibitors Composed of an Azole Scaffold.	Kyoto Prefectural University of Medicine
27524313	33	Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties.	Genentech
30964293	40	Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR? Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.	Chinese Academy of Sciences
31257087	243	Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as ROR?t inverse agonists.	Bristol-Myers Squibb
31272795	154	Discovery and pharmacological evaluation of indole derivatives as potent and selective ROR?t inverse agonist for multiple autoimmune conditions.	Advinus Therapeutics
31638797	193	Rationally Designed, Conformationally Constrained Inverse Agonists of ROR?t-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.	Bristol-Myers Squibb
31729873	43	Structure-Based and Property-Driven Optimization of	Global Discovery Chemistry
31223457	71	Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.	Astrazeneca
30130103	90	Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.	Karo Pharma
30301676	91	Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR?t) inhibitor, S18-000003.	Shionogi
30077610	25	Development of novel silanol-based human pregnane X receptor (PXR) agonists with improved receptor selectivity.	The University of Tokyo
29571573	34	Sulfoximines as potent ROR? inverse agonists.	Nestle Skin Health
29534930	34	Identification of an aminothiazole series of ROR? modulators.	The Scripps Research Institute
29233651	121	Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR?/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.	Bristol-Myers Squibb
30095900	109	Potent and Orally Bioavailable Inverse Agonists of ROR?t Resulting from Structure-Based Design.	Astrazeneca
29990434	24	Optimizing a Weakly Binding Fragment into a Potent ROR?t Inverse Agonist with Efficacy in an in Vivo Inflammation Model.	TBA
18341296	7	Diversity-oriented fluorescence library approach (DOFLA) to the discovery of chymotrypsin sensor.	New York University
16827559	24	Synthesis of tetramic and tetronic acids as beta-secretase inhibitors.	Darmstadt Technical University
16621571	29	Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.	Abbott Laboratories